WO2004031411A3 - Genes and polypeptides relating to human pancreatic cancers - Google Patents

Genes and polypeptides relating to human pancreatic cancers Download PDF

Info

Publication number
WO2004031411A3
WO2004031411A3 PCT/JP2003/011713 JP0311713W WO2004031411A3 WO 2004031411 A3 WO2004031411 A3 WO 2004031411A3 JP 0311713 W JP0311713 W JP 0311713W WO 2004031411 A3 WO2004031411 A3 WO 2004031411A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
pancreatic cancers
human pancreatic
polypeptides relating
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/011713
Other languages
French (fr)
Other versions
WO2004031411A2 (en
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
University of Tokyo NUC
Original Assignee
Oncotherapy Science Inc
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2004541224A priority Critical patent/JP4679149B2/en
Priority to DE60325628T priority patent/DE60325628D1/en
Priority to CN038255073A priority patent/CN1703524B/en
Priority to US10/529,592 priority patent/US7601826B2/en
Priority to EP03799104A priority patent/EP1556518B1/en
Priority to AU2003260966A priority patent/AU2003260966A1/en
Priority to CA002500472A priority patent/CA2500472A1/en
Application filed by Oncotherapy Science Inc, University of Tokyo NUC filed Critical Oncotherapy Science Inc
Publication of WO2004031411A2 publication Critical patent/WO2004031411A2/en
Publication of WO2004031411A3 publication Critical patent/WO2004031411A3/en
Anticipated expiration legal-status Critical
Priority to US12/551,372 priority patent/US7943730B2/en
Priority to US13/079,274 priority patent/US20120028262A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present application provides novel human genes C1958V1 or C1958V2 whose expression is markedly elevated in pancreatic cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of pancreatic cancer, and as target molecules for developing drugs against the disease.
PCT/JP2003/011713 2002-09-30 2003-09-12 Genes and polypeptides relating to human pancreatic cancers Ceased WO2004031411A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE60325628T DE60325628D1 (en) 2002-09-30 2003-09-12 GENES AND POLYPEPTIDES IN CONNECTION WITH HUMAN PANCREATIC CARCINOMAS
CN038255073A CN1703524B (en) 2002-09-30 2003-09-12 Genes and peptides related to human pancreatic cancer
US10/529,592 US7601826B2 (en) 2002-09-30 2003-09-12 Genes and polypeptides relating to human pancreatic cancers
EP03799104A EP1556518B1 (en) 2002-09-30 2003-09-12 Genes and polypeptides relating to human pancreatic cancers
AU2003260966A AU2003260966A1 (en) 2002-09-30 2003-09-12 Genes and polypeptides relating to human pancreatic cancers
JP2004541224A JP4679149B2 (en) 2002-09-30 2003-09-12 Genes and polypeptides related to human pancreatic cancer
CA002500472A CA2500472A1 (en) 2002-09-30 2003-09-12 Genes and polypeptides relating to human pancreatic cancers
US12/551,372 US7943730B2 (en) 2002-09-30 2009-08-31 Genes and polypeptides relating to human pancreatic cancers
US13/079,274 US20120028262A1 (en) 2002-09-30 2011-04-04 Genes and polypeptides relating to human pancreatic cancers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41487202P 2002-09-30 2002-09-30
US60/414,872 2002-09-30
US45088903P 2003-02-28 2003-02-28
US60/450,889 2003-02-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/529,592 A-371-Of-International US7601826B2 (en) 2002-09-30 2003-09-12 Genes and polypeptides relating to human pancreatic cancers
US12/551,372 Division US7943730B2 (en) 2002-09-30 2009-08-31 Genes and polypeptides relating to human pancreatic cancers

Publications (2)

Publication Number Publication Date
WO2004031411A2 WO2004031411A2 (en) 2004-04-15
WO2004031411A3 true WO2004031411A3 (en) 2004-09-30

Family

ID=32073343

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2003/011713 Ceased WO2004031411A2 (en) 2002-09-30 2003-09-12 Genes and polypeptides relating to human pancreatic cancers
PCT/JP2003/011817 Ceased WO2004031412A2 (en) 2002-09-30 2003-09-17 Method for diagnosing pancreatic cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/011817 Ceased WO2004031412A2 (en) 2002-09-30 2003-09-17 Method for diagnosing pancreatic cancer

Country Status (10)

Country Link
US (3) US7601826B2 (en)
EP (3) EP1556518B1 (en)
JP (2) JP4679149B2 (en)
CN (1) CN1703524B (en)
AT (2) ATE419391T1 (en)
AU (2) AU2003260966A1 (en)
CA (2) CA2500472A1 (en)
DE (2) DE60325628D1 (en)
ES (1) ES2320443T3 (en)
WO (2) WO2004031411A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
DK2537942T3 (en) 2004-05-21 2015-12-14 Trustees Of The University Of Arkansas System Board Of Use of genudtryksprofilering to predict survival in cancer patients
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2006038904A2 (en) * 2004-08-06 2006-04-13 Applera Corporation Method and compositions for treating diseases targeting e-cadherin
DE102004042822A1 (en) * 2004-08-31 2006-03-16 Technische Universität Dresden Compounds and methods of treatment, diagnosis and prognosis in pancreatic diseases
DE102004049897B4 (en) * 2004-10-13 2007-11-22 Sirs-Lab Gmbh Method for distinguishing between non-infectious and infectious causes of multiple organ failure
EP1917274A2 (en) * 2005-07-28 2008-05-07 Oncotherapy Science, Inc. Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
JP5405110B2 (en) * 2005-09-19 2014-02-05 ベリデックス・エルエルシー Methods and materials for identifying primary lesions of cancer of unknown primary
CN101415440A (en) 2006-02-10 2009-04-22 肿瘤疗法科学股份有限公司 Method for treating lung cancer
US8003098B2 (en) 2006-02-28 2011-08-23 Oncotherapy Science, Inc. Methods for damaging cells using effector functions of anti-EphA4 antibodies
EP1991872A1 (en) * 2006-03-02 2008-11-19 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein
CN1904072B (en) * 2006-07-28 2012-07-18 浙江大学 Gene composition for screening pancreatic catheter gland cancer and its application
JP2010501161A (en) * 2006-08-18 2010-01-21 オンコセラピー・サイエンス株式会社 Treatment or prevention of cancers that overexpress REG4 or KIAA0101
US7811778B2 (en) * 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
CA2681899C (en) 2007-03-27 2018-06-19 Immunovia Ab Methods for diagnosis of pancreatic adenocarcinoma, and biomarkers and arrays for use in the same
EP2189471B1 (en) 2007-08-20 2017-10-04 Oncotherapy Science, Inc. Foxm1 peptide and medicinal agent comprising the same
ES2632123T3 (en) * 2007-08-20 2017-09-11 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
ES2534437T3 (en) 2008-06-30 2015-04-22 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010023866A1 (en) * 2008-08-27 2010-03-04 Oncotherapy Science, Inc. Syngr4 for target genes of cancer therapy and diagnosis
WO2012006632A2 (en) 2010-07-09 2012-01-12 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100135991A1 (en) * 2008-11-17 2010-06-03 Chiu-Chen Huang Antibodies recognizing oxygen-regulated protein 150 expressed on cancer cells and methods of using same
TWI469791B (en) 2009-02-18 2015-01-21 Oncotherapy Science Inc Foxm1 peptides and vaccines containing the same
DE102010043541B4 (en) * 2009-12-16 2012-01-26 Technische Universität Dresden Method and means for predicting survival in pancreatic carcinoma by analysis of biomarkers
WO2011080796A1 (en) 2009-12-28 2011-07-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies and uses thereof
US20130137748A1 (en) * 2010-02-03 2013-05-30 Oncotherapy Science, Inc. Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis
EP3355057A3 (en) * 2010-06-01 2018-12-12 Metanomics Health GmbH Means and methods for diagnosing pancreatic cancer in a subject
SG187045A1 (en) 2010-08-13 2013-02-28 Somalogic Inc Pancreatic cancer biomarkers and uses thereof
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
KR101297336B1 (en) 2011-03-30 2013-08-14 인하대학교 산학협력단 Device For Classifying Mucinous Cystadenoma
KR101223598B1 (en) 2011-04-06 2013-01-22 인하대학교 산학협력단 A System for Diagnosing Pancreatic Intraepithelial Neoplasia
GB2510539B (en) * 2011-10-24 2016-04-20 Gen Hospital Corp Biomarkers of cancer
WO2014189843A1 (en) 2013-05-20 2014-11-27 Board Of Trustees Of The University Of Arkansas Gep5 model for multiple myeloma
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
EP3119908A4 (en) * 2014-03-11 2018-02-21 The Council Of The Queensland Institute Of Medical Research Determining cancer aggressiveness, prognosis and responsiveness to treatment
US10451628B2 (en) * 2014-05-07 2019-10-22 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
US10301624B2 (en) 2014-06-25 2019-05-28 The General Hospital Corporation Targeting human satellite II (HSATII)
ES2843829T3 (en) * 2014-09-26 2021-07-20 Hi Stem Ggmbh Im Deutschen Krebsforschungszentrum Dkfz New methods for subtyping and cancer treatment
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
JP2018136122A (en) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター Blood plasma biomarker panel for diagnosing pancreas cancer
CN105017403B (en) * 2015-07-09 2018-07-03 陈勇 The preparation and its application of cancer of pancreas related polypeptide DAP44 monoclonal antibodies
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
CN111566213B (en) * 2017-09-11 2023-08-04 国立大学法人北海道大学 cancer treatment drugs
EP3508855A1 (en) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Method for the selection of patients and kit
US12582702B2 (en) * 2018-05-11 2026-03-24 University Of Massachusetts Methods for improving leptin sensitivity for the treatment of obesity and diabetes
KR102328654B1 (en) * 2019-04-17 2021-11-19 한국원자력의학원 A composition for preventing or treating cancer
KR102289278B1 (en) * 2019-07-09 2021-08-13 주식회사 베르티스 Biomarker panel for diagnosis of pancreatic cancer and its use
IL299827B1 (en) 2020-07-15 2026-04-01 Cerebral Therapeutics Inc Medical system including two access ports
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode
CN115074365B (en) * 2022-06-28 2023-02-28 中国医学科学院北京协和医院 sgRNA targeting GATM gene and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031274A2 (en) * 1997-12-15 1999-06-24 Abbott Laboratories Reagents and methods useful for detecting diseases of the pancreas
WO1999067386A2 (en) * 1998-06-23 1999-12-29 Chiron Corporation Differentially expressed genes in pancreatic cancer and displasia
WO2001055314A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Digestive system related nucleic acids, proteins and antibodies
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6429302B1 (en) * 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6333152B1 (en) 1997-05-21 2001-12-25 The Johnshopkins University Gene expression profiles in normal and cancer cells
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001009318A1 (en) 1999-07-29 2001-02-08 Helix Research Institute Liver cancer-associated genes
EP1672070A3 (en) 1999-12-01 2006-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
EP1504099A4 (en) 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2004031410A2 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
EP1991872A1 (en) * 2006-03-02 2008-11-19 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031274A2 (en) * 1997-12-15 1999-06-24 Abbott Laboratories Reagents and methods useful for detecting diseases of the pancreas
WO1999067386A2 (en) * 1998-06-23 1999-12-29 Chiron Corporation Differentially expressed genes in pancreatic cancer and displasia
US6429302B1 (en) * 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
WO2001055314A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Digestive system related nucleic acids, proteins and antibodies
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRNOGORAC-JURCEVIC TATJANA ET AL: "Expression profiling of microdissected pancreatic adenocarcinomas", ONCOGENE, vol. 21, no. 29, 4 July 2002 (2002-07-04), pages 4587 - 4594, XP002267283, ISSN: 0950-9232 *
GRESS TM ET AL: "A PANCREATIC CANCER-SPECIFIC EXPRESSION PROFILE", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 13, 1996, pages 1819 - 1830, XP002916550, ISSN: 0950-9232 *
HAN HAIYONG ET AL: "Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray", CANCER RESEARCH, vol. 62, no. 10, 15 May 2002 (2002-05-15), pages 2890 - 2896, XP002267297, ISSN: 0008-5472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer

Also Published As

Publication number Publication date
WO2004031411A2 (en) 2004-04-15
CN1703524B (en) 2010-04-07
US20120028262A1 (en) 2012-02-02
EP1556518B1 (en) 2008-12-31
EP1549771A2 (en) 2005-07-06
DE60325617D1 (en) 2009-02-12
AU2003260966A8 (en) 2004-04-23
ES2320443T3 (en) 2009-05-22
JP4679149B2 (en) 2011-04-27
US7943730B2 (en) 2011-05-17
US20100093629A1 (en) 2010-04-15
AU2003263603A1 (en) 2004-04-23
JP2006500948A (en) 2006-01-12
US7601826B2 (en) 2009-10-13
EP1549771B1 (en) 2008-12-31
CN1703524A (en) 2005-11-30
US20060270619A1 (en) 2006-11-30
EP2009117A3 (en) 2009-03-18
DE60325628D1 (en) 2009-02-12
EP2009117A2 (en) 2008-12-31
ATE419391T1 (en) 2009-01-15
WO2004031412A2 (en) 2004-04-15
CA2500472A1 (en) 2004-04-15
AU2003260966A1 (en) 2004-04-23
ATE419390T1 (en) 2009-01-15
WO2004031412A3 (en) 2004-07-15
CA2500482A1 (en) 2004-04-15
AU2003263603A8 (en) 2004-04-23
EP1556518A2 (en) 2005-07-27
JP2006500947A (en) 2006-01-12

Similar Documents

Publication Publication Date Title
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
SG145559A1 (en) Genes and polypeptides relating to human colon cancers
WO2008018642A3 (en) Genes and polypeptides relating to breast cancers
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
WO2002074156A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2004065423A3 (en) Recognition molecules for the treatment and detection of tumours
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002060317A3 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2002012328A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002058534A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2005054295A8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
WO2003037267A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2006016525A3 (en) Genes and polypeptides relating to breast cancers
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2003086175A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
EP1961819A3 (en) Composition and methods for the therapy and diagnosis of lung cancer
WO2005055925A8 (en) 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004541224

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2500472

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003799104

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038255073

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003799104

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006270619

Country of ref document: US

Ref document number: 10529592

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10529592

Country of ref document: US